Sartorius (OTCMKTS:SARTF) Raised to “Buy” at Zacks Investment Research
Zacks Investment Research upgraded shares of Sartorius (OTCMKTS:SARTF) from a hold rating to a buy rating in a report issued on Wednesday morning, Zacks.com reports. They currently have $192.00 price objective on the stock.
According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “
Separately, DZ Bank restated a sell rating on shares of Sartorius in a research note on Friday, July 19th.
Sartorius Company Profile
There is no company description available for Sartorius AG.
Featured Article: 12b-1 Fees
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.